Alzheimer's vaccine effective in mice
ROCHESTER, N.Y. (UPI) -- University of Rochester Medical Center scientists say their vaccine prevents the development of Alzheimer's disease-like pathology in mice. The researchers say the vaccinated mice generated an immune response to the protein known as amyloid-beta peptide, which accumulates in what are called "amyloid plaques" in brains of people with Alzheimer's. The study, published in Molecular Therapy, says the vaccinated mice demonstrated normal learning skills and functioning memory in spite of being genetically designed to develop an aggressive form of Alzheimer's disease. "Our study demonstrates that we can create a potent but safe version of a vaccine that utilizes the strategy of immune response shaping to prevent Alzheimer's-related pathologies and memory deficits," lead author William Bowers says in a statement. "The vaccinated mice not only performed better, we found no evidence of signature amyloid plaque in their brains." Bowers expects the vaccine eventually to be tested in people, but due to the number of studies required to satisfy regulatory requirements, it could be three or more years before human trials could occur.
Copyright 2008 by United Press International
ROCHESTER, N.Y. (UPI) -- University of Rochester Medical Center scientists say their vaccine prevents the development of Alzheimer's disease-like pathology in mice. The researchers say the vaccinated mice generated an immune response to the protein known as amyloid-beta peptide, which accumulates in what are called "amyloid plaques" in brains of people with Alzheimer's. The study, published in Molecular Therapy, says the vaccinated mice demonstrated normal learning skills and functioning memory in spite of being genetically designed to develop an aggressive form of Alzheimer's disease. "Our study demonstrates that we can create a potent but safe version of a vaccine that utilizes the strategy of immune response shaping to prevent Alzheimer's-related pathologies and memory deficits," lead author William Bowers says in a statement. "The vaccinated mice not only performed better, we found no evidence of signature amyloid plaque in their brains." Bowers expects the vaccine eventually to be tested in people, but due to the number of studies required to satisfy regulatory requirements, it could be three or more years before human trials could occur.
Copyright 2008 by United Press International
No comments:
Post a Comment